Search Results

Masimo, announced that the Masimo W1® Sport advanced health tracking wearable is gaining a powerful new feature: scientifically based sleep analysis with Sleep Halo™.

Indica Labs announced today that it received FDA clearance for HALO AP Dx, an enterprise digital pathology platform, for primary diagnosis.

Nexalin Technology, Inc. announces that the U.S. Food and Drug Administration has provided feedback and reached consensus on the design for its planned clinical studies in anxiety and insomnia for its new Gen-3 HALO Clarity™, a non-invasive, Deep Intracranial Frequency Stimulation headset device designed to address the global mental health epidemic.

Indica Labs, an industry leader in AI-powered digital pathology solutions, and Hamamatsu Photonics K.K., a pioneer in whole slide imaging systems, announce that the U.S. Food and Drug Administration (FDA) has issued a 510(k) clearance to Indica Labs for HALO AP Dx, an enterprise digital pathology platform.

Nexalin Technology, Inc. today unveiled its Gen-3 HALO™ Clarity 15 milliamp (mA) neurostimulation device designed to treat a variety of mental health conditions, including Major Depressive Disorder (MDD).

HALO Precision Diagnostics (“HALO”), a leader in early disease detection using precision diagnostics, today announced a collaboration with Bayer, a global leader in radiology, to join QUANTI, Bayer’s Phase III clinical development program for gadoquatrane.

Noramco announced its launch of the Noramco Group, a newly created comprehensive North American-based supply chain solution including subsidiaries Purisys, Noramco, and the newly acquired drug product CDMO, Halo Pharma.